董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald R. Chase | 男 | Director | 76 | 14.17万美元 | 未持股 | 2023-05-10 |
| Neil Dey | 男 | President, Chief Executive Officer and Director | 59 | 42.54万美元 | 未持股 | 2023-05-10 |
| Douglas C. Wurth | 男 | Director,Chairman of the Board | 58 | 15.42万美元 | 未持股 | 2023-05-10 |
| Svetlana Dey | 女 | Director | 51 | 10.67万美元 | 未持股 | 2023-05-10 |
| Gary Gemignani | 男 | Director | 57 | 8.00万美元 | 未持股 | 2023-05-10 |
| Fred S. Zeidman | 男 | Director | 76 | 10.50万美元 | 未持股 | 2023-05-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil Dey | 男 | President, Chief Executive Officer and Director | 59 | 42.54万美元 | 未持股 | 2023-05-10 |
| Jason Cook | 男 | Chief Technology Officer | 41 | 28.31万美元 | 未持股 | 2023-05-10 |
| Kenneth Fisher | 男 | Chief Financial Officer | 44 | 37.42万美元 | 未持股 | 2023-05-10 |
董事简历
中英对照 | 中文 | 英文- Donald R. Chase
-
Donald R. Chase，自1972年起在Westbank任职，并担任若干不同级别的职务。1987年， Mr. Chase被任命为Westban董事会董事，1988年12月被任命为总裁兼首席执行官。1990年9月，In September 1990 Mr. Chase被任命为Westbank Corporatio董事和公司总裁兼首席执行官。
Donald R. Chase,has served on Bluejay Diagnostics, Inc. Board since 2017. Mr. Chase has been a member of the Board of Directors of Millyard Bank since 2020. Mr. Chase was a member of the Board of Directors of Merchants Bank and Merchants Bancshares, Inc., in South Burlington. VT, from 2015 through 2017. Mr. Chase was Chairman of the Board of NUVO Bank and Trust Company of Springfield, Massachusetts since its inception in 2008 through 2015. Mr. Chase served as President and Chief Executive Officer, Vice Chairman, and a Director of Westbank Corporation and its wholly-owned subsidiary, Westbank from 1988 to 2007. Mr. Chase is active in a number of commercial real estate, farming and ranching activities and serves in a number of civic roles. He is former Chairman of the Board of Trustees for the Eastern States Exposition in West Springfield, MA. Mr. Chase is also a commissioner of the Board of Public Safety for the City of West Springfield, MA and is a former member of the Massachusetts Board of Agriculture. Mr. Chase is a veteran of the United States Army during which he served in combat in Vietnam from 1967 through 1969. Mr. Chase graduated with honors from Western New England University with a Bachelor of Science degree in Accounting. - Donald R. Chase，自1972年起在Westbank任职，并担任若干不同级别的职务。1987年， Mr. Chase被任命为Westban董事会董事，1988年12月被任命为总裁兼首席执行官。1990年9月，In September 1990 Mr. Chase被任命为Westbank Corporatio董事和公司总裁兼首席执行官。
- Donald R. Chase,has served on Bluejay Diagnostics, Inc. Board since 2017. Mr. Chase has been a member of the Board of Directors of Millyard Bank since 2020. Mr. Chase was a member of the Board of Directors of Merchants Bank and Merchants Bancshares, Inc., in South Burlington. VT, from 2015 through 2017. Mr. Chase was Chairman of the Board of NUVO Bank and Trust Company of Springfield, Massachusetts since its inception in 2008 through 2015. Mr. Chase served as President and Chief Executive Officer, Vice Chairman, and a Director of Westbank Corporation and its wholly-owned subsidiary, Westbank from 1988 to 2007. Mr. Chase is active in a number of commercial real estate, farming and ranching activities and serves in a number of civic roles. He is former Chairman of the Board of Trustees for the Eastern States Exposition in West Springfield, MA. Mr. Chase is also a commissioner of the Board of Public Safety for the City of West Springfield, MA and is a former member of the Massachusetts Board of Agriculture. Mr. Chase is a veteran of the United States Army during which he served in combat in Vietnam from 1967 through 1969. Mr. Chase graduated with honors from Western New England University with a Bachelor of Science degree in Accounting.
- Neil Dey
-
Neil Dey于2015年共同创立了Bluejay Diagnostics。2008年，Dey先生联合创立了Lana Management and Business Research International，LLC“；LMBRI”；，并从2008年到2015年担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国，日本和欧盟医疗领域的产品发布和营销。任职LMBRI公司期间，他曾担任Toray Industries公司、Hitachi Chemicals公司（现为Showa Denko Materials Co.Ltd.）、Fujifilm公司（富士化学公司）、Merck&Co公司、SRI International公司等公司的顾问约8年。从2005年到2007年，Dey先生担任Definines，AG的业务开发和市场副总裁。从2001年到2005年，他曾担任Impath公司的美国西部业务开发主管，在那里他曾负责三个业务单元，以及Herceptin公司的乳腺癌治疗的HER2NEU Diagnostics的推出。较早的职位包括Genmethrax，Inc.的首席商务官；Thomas Jefferson Medical University的技术许可经理；Ciba Geigy（诺华）的技术许可经理。Dey先生在印度的Visva-Bharati大学获得了生物化学学士学位和理学硕士学位，并在匈牙利的生物研究中心获得了脂膜生物化学博士学位。他还获得了剑桥大学的工商管理硕士学位（富布赖特奖学金）。
Neil Dey,co-founded Bluejay Diagnostics in 2015. In 2008, Mr. Dey co-founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and EU. During his tenure with LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva-Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's in Business Administration (Fulbright Scholarship) from the University of Cambridge. - Neil Dey于2015年共同创立了Bluejay Diagnostics。2008年，Dey先生联合创立了Lana Management and Business Research International，LLC“；LMBRI”；，并从2008年到2015年担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国，日本和欧盟医疗领域的产品发布和营销。任职LMBRI公司期间，他曾担任Toray Industries公司、Hitachi Chemicals公司（现为Showa Denko Materials Co.Ltd.）、Fujifilm公司（富士化学公司）、Merck&Co公司、SRI International公司等公司的顾问约8年。从2005年到2007年，Dey先生担任Definines，AG的业务开发和市场副总裁。从2001年到2005年，他曾担任Impath公司的美国西部业务开发主管，在那里他曾负责三个业务单元，以及Herceptin公司的乳腺癌治疗的HER2NEU Diagnostics的推出。较早的职位包括Genmethrax，Inc.的首席商务官；Thomas Jefferson Medical University的技术许可经理；Ciba Geigy（诺华）的技术许可经理。Dey先生在印度的Visva-Bharati大学获得了生物化学学士学位和理学硕士学位，并在匈牙利的生物研究中心获得了脂膜生物化学博士学位。他还获得了剑桥大学的工商管理硕士学位（富布赖特奖学金）。
- Neil Dey,co-founded Bluejay Diagnostics in 2015. In 2008, Mr. Dey co-founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and EU. During his tenure with LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva-Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's in Business Administration (Fulbright Scholarship) from the University of Cambridge.
- Douglas C. Wurth
-
Douglas C.Wurth自2017年以来一直担任Bluejay Diagnostics的董事会主席。自2016年以来，Wurth先生一直是私人投资者。Wurth先生自2021年2月起担任Good Works II Acquisition Corp.的首席执行官兼董事，自2020年10月起担任Good Works Acquisition Corp.的联合主席。1997年至2016年，Wurth先生在摩根大通工作了近20年，期间领导了摩根大通资产管理公司的主要业务。他曾担任资产管理另类投资的首席执行官，以及J.P.Morgan公司的国际私人银行的首席执行官，在那里他曾领导特许经营在亚洲、拉丁美洲和欧洲的扩张，同时常驻纽约、香港和伦敦。自离开J.P.Morgan以来，他投资并帮助领导几家私人公司，他是Standard Power和Vestrata的董事会主席，以及Triax Technologies的董事会成员。加入J.P.Morgan之前，1992年至1995年，Wurth先生在纽约公司Skadden，Arps，Slate，Meagher&Flom从事法律工作，并担任前美国参议员Robert Dole1996年总统竞选的总法律顾问。Wurth先生在圣母大学获得文学学士学位，并在弗吉尼亚大学法学院获得法学博士学位。
Douglas C. Wurth,has served as Chairman of the Board of Bluejay Diagnostics since 2017. Since 2016, Mr. Wurth has been a private investor. Mr. Wurth has served as Chief Executive Officer and a Director of Good Works II Acquisition Corp. since February 2021, and Co- Chairman of Good Works Acquisition Corp. since October 2020. Mr. Wurth led major businesses within J.P. Morgan Asset Management during his nearly 20 years at J.P Morgan from 1997 to 2016. Mr. Wurth was the Chief Executive Officer of Alternative Investments in Asset Management, and Chief Executive Officer of J.P. Morgan's International Private Bank, where he led the expansion of the franchise in Asia, Latin America and Europe while based in New York, Hong Kong, and London. Since leaving J.P. Morgan, Mr. Wurth has invested in and helped lead several private companies, of which he is Chairman of the Board of Standard Power and Vestrata, and a board member of Triax Technologies. Before joining J.P. Morgan, Mr. Wurth practiced law at the New York firm Skadden, Arps, Slate, Meagher & Flom from 1992 to 1995, and served as General Counsel to former U.S. Senator Robert Dole's 1996 presidential campaign. Mr. Wurth earned a Bachelor of Arts degree from the University of Notre Dame and a J.D. from the University of Virginia School of Law. - Douglas C.Wurth自2017年以来一直担任Bluejay Diagnostics的董事会主席。自2016年以来，Wurth先生一直是私人投资者。Wurth先生自2021年2月起担任Good Works II Acquisition Corp.的首席执行官兼董事，自2020年10月起担任Good Works Acquisition Corp.的联合主席。1997年至2016年，Wurth先生在摩根大通工作了近20年，期间领导了摩根大通资产管理公司的主要业务。他曾担任资产管理另类投资的首席执行官，以及J.P.Morgan公司的国际私人银行的首席执行官，在那里他曾领导特许经营在亚洲、拉丁美洲和欧洲的扩张，同时常驻纽约、香港和伦敦。自离开J.P.Morgan以来，他投资并帮助领导几家私人公司，他是Standard Power和Vestrata的董事会主席，以及Triax Technologies的董事会成员。加入J.P.Morgan之前，1992年至1995年，Wurth先生在纽约公司Skadden，Arps，Slate，Meagher&Flom从事法律工作，并担任前美国参议员Robert Dole1996年总统竞选的总法律顾问。Wurth先生在圣母大学获得文学学士学位，并在弗吉尼亚大学法学院获得法学博士学位。
- Douglas C. Wurth,has served as Chairman of the Board of Bluejay Diagnostics since 2017. Since 2016, Mr. Wurth has been a private investor. Mr. Wurth has served as Chief Executive Officer and a Director of Good Works II Acquisition Corp. since February 2021, and Co- Chairman of Good Works Acquisition Corp. since October 2020. Mr. Wurth led major businesses within J.P. Morgan Asset Management during his nearly 20 years at J.P Morgan from 1997 to 2016. Mr. Wurth was the Chief Executive Officer of Alternative Investments in Asset Management, and Chief Executive Officer of J.P. Morgan's International Private Bank, where he led the expansion of the franchise in Asia, Latin America and Europe while based in New York, Hong Kong, and London. Since leaving J.P. Morgan, Mr. Wurth has invested in and helped lead several private companies, of which he is Chairman of the Board of Standard Power and Vestrata, and a board member of Triax Technologies. Before joining J.P. Morgan, Mr. Wurth practiced law at the New York firm Skadden, Arps, Slate, Meagher & Flom from 1992 to 1995, and served as General Counsel to former U.S. Senator Robert Dole's 1996 presidential campaign. Mr. Wurth earned a Bachelor of Arts degree from the University of Notre Dame and a J.D. from the University of Virginia School of Law.
- Svetlana Dey
-
自2015年以来，Svetlana Dey一直是Bluejay董事会的成员。Dey女士于2015年共同创立了Bluejay Diagnostics。她还于2008年联合创立了LMBRI，这是一家管理咨询公司，专注于美国、日本和印度医疗领域的产品发布和营销。自2008年以来，Dey女士一直担任LMBRI的总裁兼首席执行官。Dey女士是Laminar Pharma，Inc.的董事会成员。在加入LMBRI之前，Dey女士在医疗保健咨询企业工作了15年以上。在这些职位上，她参与了医疗保健和生命科学产品开发、销售和营销运营以及综合管理的管理和运营超过12年。Dey女士获得了俄罗斯马里埃尔共和国国立大学的数学硕士学位。
Svetlana Dey,has been a member of Bluejay's Board since 2015. Ms. Dey co-founded Bluejay Diagnostics in 2015. She also co-founded LMBRI in 2008, a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and India. Ms. Dey has served as LMBRI's President and CEO since 2008. Prior to LMBRI, Ms. Dey spent more than 15 years in healthcare consulting businesses. In these roles, she has been involved in management and operations of healthcare and life sciences products development, sales and marketing operations and general management. Ms. Dey earned a Master's Degree in Mathematics from the State University of Mari El Republic, Russia. - 自2015年以来，Svetlana Dey一直是Bluejay董事会的成员。Dey女士于2015年共同创立了Bluejay Diagnostics。她还于2008年联合创立了LMBRI，这是一家管理咨询公司，专注于美国、日本和印度医疗领域的产品发布和营销。自2008年以来，Dey女士一直担任LMBRI的总裁兼首席执行官。Dey女士是Laminar Pharma，Inc.的董事会成员。在加入LMBRI之前，Dey女士在医疗保健咨询企业工作了15年以上。在这些职位上，她参与了医疗保健和生命科学产品开发、销售和营销运营以及综合管理的管理和运营超过12年。Dey女士获得了俄罗斯马里埃尔共和国国立大学的数学硕士学位。
- Svetlana Dey,has been a member of Bluejay's Board since 2015. Ms. Dey co-founded Bluejay Diagnostics in 2015. She also co-founded LMBRI in 2008, a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and India. Ms. Dey has served as LMBRI's President and CEO since 2008. Prior to LMBRI, Ms. Dey spent more than 15 years in healthcare consulting businesses. In these roles, she has been involved in management and operations of healthcare and life sciences products development, sales and marketing operations and general management. Ms. Dey earned a Master's Degree in Mathematics from the State University of Mari El Republic, Russia.
- Gary Gemignani
-
Gary Gemignani将在本次发行结束时加入我们Bluejay的董事会。自2020年1月以来，Gemignani先生一直担任Acacia Pharma Group plc（一家医院制药公司）的执行副总裁，首席财务官。在加入Acacia Pharma之前，Gemignani先生于2017年至2019年担任Synergy Pharmaceuticals Inc.的首席财务官，在那里他成功地领导了将这家纳斯达克上市公司的资产出售给Bausch Health。Synergy Pharmaceuticals Inc.于2018年12月根据《美国破产法》第11章向纽约南区美国破产法院提交了请愿书。此前，Gemignani先生曾担任Biodel Inc.的首席执行官兼首席财务官，负责监督该公司的业务和战略规划、运营和融资活动。在此之前，Gemignani先生在多个公共和私人公司担任高级和执行财务和运营职务，包括Prudential Financial，Gentium，Novartis和Wyeth。Gemignani先生在Arthur Andersen&Co.开始了他的职业生涯。
Gary Gemignani,joined Bluejay's Board in November 2021. Mr. Gemignani previously served as EVP, Chief Financial Officer of Solta Medical, a division of Bausch Health. Prior to Solta Medical, Mr. Gemignani served as EVP and CFO of Acacia Pharma Group plc from 2020 to 2022. Prior to Acacia Pharma he served as CFO of Synergy Pharmaceuticals Inc. from 2017 to 2019 where he successfully led the sale of this Nasdaq-listed company's assets to Bausch Health. Synergy Pharmaceuticals Inc. filed a petition in the United States Bankruptcy Court for the Southern District of New York in December 2018 under Chapter 11 of the U.S. Bankruptcy Code. Previously, Mr. Gemignani served as CEO and CFO of Biodel Inc., overseeing business and strategic planning, operations and financing activities of the company. Prior to this, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including Prudential Financial, Gentium, Novartis and Wyeth. - Gary Gemignani将在本次发行结束时加入我们Bluejay的董事会。自2020年1月以来，Gemignani先生一直担任Acacia Pharma Group plc（一家医院制药公司）的执行副总裁，首席财务官。在加入Acacia Pharma之前，Gemignani先生于2017年至2019年担任Synergy Pharmaceuticals Inc.的首席财务官，在那里他成功地领导了将这家纳斯达克上市公司的资产出售给Bausch Health。Synergy Pharmaceuticals Inc.于2018年12月根据《美国破产法》第11章向纽约南区美国破产法院提交了请愿书。此前，Gemignani先生曾担任Biodel Inc.的首席执行官兼首席财务官，负责监督该公司的业务和战略规划、运营和融资活动。在此之前，Gemignani先生在多个公共和私人公司担任高级和执行财务和运营职务，包括Prudential Financial，Gentium，Novartis和Wyeth。Gemignani先生在Arthur Andersen&Co.开始了他的职业生涯。
- Gary Gemignani,joined Bluejay's Board in November 2021. Mr. Gemignani previously served as EVP, Chief Financial Officer of Solta Medical, a division of Bausch Health. Prior to Solta Medical, Mr. Gemignani served as EVP and CFO of Acacia Pharma Group plc from 2020 to 2022. Prior to Acacia Pharma he served as CFO of Synergy Pharmaceuticals Inc. from 2017 to 2019 where he successfully led the sale of this Nasdaq-listed company's assets to Bausch Health. Synergy Pharmaceuticals Inc. filed a petition in the United States Bankruptcy Court for the Southern District of New York in December 2018 under Chapter 11 of the U.S. Bankruptcy Code. Previously, Mr. Gemignani served as CEO and CFO of Biodel Inc., overseeing business and strategic planning, operations and financing activities of the company. Prior to this, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including Prudential Financial, Gentium, Novartis and Wyeth.
- Fred S. Zeidman
-
Fred S. Zeidman，自2011年9月以来一直是Petroflow能源公司的董事长，以及自2013年4月以来一直在Petro River Oil Corporation公司任董事。自2009年以来任Hyperdynamics公司的董事，自1986年以来任Prosperity Bancshares股份有限公司的董事。自2004年以来一直是Are一家misSoft Liquidating Trust的一位受托人。2013年3月，被任命为Nova Biosource Fuels, Inc. （"Nova"）（一家公开上市的生物石油科技公司）的临时总裁，并一直任到2009年11月该公司的收购。Zeidman先生还曾于2007年6月-2009年11月期间，在Nova任董事。2009年8月-2009年11月期间，他曾在Transmeridian Exploration股份有限公司任首席重组官，并且一直任到2009年11月该公司的售出。他曾在Prosperity Bank工作了26年。他还曾于2002年6月一直到2007年2月Seitel股份有限公司售出之前，在Seitel 股份有限公司（一家油田服务公司）任首席执行官、总裁兼董事长。2003年7月-2008年12月期间，在Greenberg Traurig律师事务所任总经理。他曾在各种公司担任首席执行官、临时首席执行官以及董事长，包括若干石油和天然气行业的公司。他目前是美国（U.S。） Holocaust Memorial Council的一位荣誉董事长，是于2002年3月被前总裁t George W. Bush任命为到这个职位上的，任期为2002-2010年。他目前还是Houston 德州（Texas）大学卫生科学系统的一位荣誉主席，并且在德州（Texas）心脏研究所（在那里他目前任财务总监）以及the Institute for Rehabilitation and Research （TIRR）的理事会任职他目前在Saint Thomas大学的理事会和执行委员会任职，并且管理着其发展委员会和Houston社区学院。他是在Washington大学获得文学学士学位，以及在New York大学获得工商管理学硕士学位 的。
Fred S. Zeidman,has served on Graf Global Corp. board of directors since June 25, 2024. Mr. Zeidman served as Chairman of Good Works II Acquisition Corp. from February 2021 through March 2023. He served as Chief Executive Officer and Co-Chairman of Good Works Acquisition Corp. from June 2020 until the merger with Cipher Mining in August 2021. Mr. Zeidman served as Chairman of Gordian Group LLC, a U.S. investment bank specializing in board level advice in complex financial matters from December 2014 through February 2021 and is currently Chairman of WoodRock & Co. Over the course of his distinguished 50-year career, Mr. Zeidman has served in a number of high-profile executive roles. He is also a director of Bluejay Diagnostics, Inc. (NASDAQ: BJDX), Camber Energy, Inc. (NYSE American: CEI) and Prosperity Bank in Houston. His leadership roles have included: Chairman of the Board and Chief Executive Officer of Unibar Corporation, the largest domestic independent drilling fluids company, until its sale to Anchor Drilling Fluids in 1992, President and Chief Executive Officer of Crown Services (1992 until its sale to ARS in1994), President and Chief Executive Officer of Intersystems, President and Chief Executive Officer of Interpak Systems (March 2002 to December 2007), Chairman, Chief Executive Officer and President of Seitel, Inc. (June 2002 until the sale of the company in February 2007), a Houston-based onshore seismic data provider where he was instrumental in the successful turnaround of the Company, Chief Bankruptcy Trustee of AremisSoft Corp. (1999-2002), Chief Restructuring Officer of TransMeridian Exploration Inc. (August 2009 until the sale in November 2009), a Director of the REMA subsidiary of NRG Energy, Lead Director of Straight Path Communications (July 2013 until its sale to Verizon Corp. in May 2017), and CFO of the Texas Heart Institute where he led a complex financial restructuring and assisted in the integration of St. Luke's Episcopal Hospital System and Baylor College of Medicine into Catholic Health Initiatives. Mr. Zeidman was appointed Chairman of the US Holocaust Memorial Council by President George W. Bush in 2002, and served until 2010, and he was reappointed to the Council by President Donald Trump in 2019. He was Chairman of the University of Texas Health Science System Houston. Mr. Zeidman was a Director of the Texas Heart Institute. He is on the board of the Development Corp of Israel (Israel Bonds) and served on the Board and Executive Committee of the National World War II Museum. Mr. Zeidman holds a Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University. - Fred S. Zeidman，自2011年9月以来一直是Petroflow能源公司的董事长，以及自2013年4月以来一直在Petro River Oil Corporation公司任董事。自2009年以来任Hyperdynamics公司的董事，自1986年以来任Prosperity Bancshares股份有限公司的董事。自2004年以来一直是Are一家misSoft Liquidating Trust的一位受托人。2013年3月，被任命为Nova Biosource Fuels, Inc. （"Nova"）（一家公开上市的生物石油科技公司）的临时总裁，并一直任到2009年11月该公司的收购。Zeidman先生还曾于2007年6月-2009年11月期间，在Nova任董事。2009年8月-2009年11月期间，他曾在Transmeridian Exploration股份有限公司任首席重组官，并且一直任到2009年11月该公司的售出。他曾在Prosperity Bank工作了26年。他还曾于2002年6月一直到2007年2月Seitel股份有限公司售出之前，在Seitel 股份有限公司（一家油田服务公司）任首席执行官、总裁兼董事长。2003年7月-2008年12月期间，在Greenberg Traurig律师事务所任总经理。他曾在各种公司担任首席执行官、临时首席执行官以及董事长，包括若干石油和天然气行业的公司。他目前是美国（U.S。） Holocaust Memorial Council的一位荣誉董事长，是于2002年3月被前总裁t George W. Bush任命为到这个职位上的，任期为2002-2010年。他目前还是Houston 德州（Texas）大学卫生科学系统的一位荣誉主席，并且在德州（Texas）心脏研究所（在那里他目前任财务总监）以及the Institute for Rehabilitation and Research （TIRR）的理事会任职他目前在Saint Thomas大学的理事会和执行委员会任职，并且管理着其发展委员会和Houston社区学院。他是在Washington大学获得文学学士学位，以及在New York大学获得工商管理学硕士学位 的。
- Fred S. Zeidman,has served on Graf Global Corp. board of directors since June 25, 2024. Mr. Zeidman served as Chairman of Good Works II Acquisition Corp. from February 2021 through March 2023. He served as Chief Executive Officer and Co-Chairman of Good Works Acquisition Corp. from June 2020 until the merger with Cipher Mining in August 2021. Mr. Zeidman served as Chairman of Gordian Group LLC, a U.S. investment bank specializing in board level advice in complex financial matters from December 2014 through February 2021 and is currently Chairman of WoodRock & Co. Over the course of his distinguished 50-year career, Mr. Zeidman has served in a number of high-profile executive roles. He is also a director of Bluejay Diagnostics, Inc. (NASDAQ: BJDX), Camber Energy, Inc. (NYSE American: CEI) and Prosperity Bank in Houston. His leadership roles have included: Chairman of the Board and Chief Executive Officer of Unibar Corporation, the largest domestic independent drilling fluids company, until its sale to Anchor Drilling Fluids in 1992, President and Chief Executive Officer of Crown Services (1992 until its sale to ARS in1994), President and Chief Executive Officer of Intersystems, President and Chief Executive Officer of Interpak Systems (March 2002 to December 2007), Chairman, Chief Executive Officer and President of Seitel, Inc. (June 2002 until the sale of the company in February 2007), a Houston-based onshore seismic data provider where he was instrumental in the successful turnaround of the Company, Chief Bankruptcy Trustee of AremisSoft Corp. (1999-2002), Chief Restructuring Officer of TransMeridian Exploration Inc. (August 2009 until the sale in November 2009), a Director of the REMA subsidiary of NRG Energy, Lead Director of Straight Path Communications (July 2013 until its sale to Verizon Corp. in May 2017), and CFO of the Texas Heart Institute where he led a complex financial restructuring and assisted in the integration of St. Luke's Episcopal Hospital System and Baylor College of Medicine into Catholic Health Initiatives. Mr. Zeidman was appointed Chairman of the US Holocaust Memorial Council by President George W. Bush in 2002, and served until 2010, and he was reappointed to the Council by President Donald Trump in 2019. He was Chairman of the University of Texas Health Science System Houston. Mr. Zeidman was a Director of the Texas Heart Institute. He is on the board of the Development Corp of Israel (Israel Bonds) and served on the Board and Executive Committee of the National World War II Museum. Mr. Zeidman holds a Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University.
高管简历
中英对照 | 中文 | 英文- Neil Dey
Neil Dey于2015年共同创立了Bluejay Diagnostics。2008年，Dey先生联合创立了Lana Management and Business Research International，LLC“；LMBRI”；，并从2008年到2015年担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国，日本和欧盟医疗领域的产品发布和营销。任职LMBRI公司期间，他曾担任Toray Industries公司、Hitachi Chemicals公司（现为Showa Denko Materials Co.Ltd.）、Fujifilm公司（富士化学公司）、Merck&Co公司、SRI International公司等公司的顾问约8年。从2005年到2007年，Dey先生担任Definines，AG的业务开发和市场副总裁。从2001年到2005年，他曾担任Impath公司的美国西部业务开发主管，在那里他曾负责三个业务单元，以及Herceptin公司的乳腺癌治疗的HER2NEU Diagnostics的推出。较早的职位包括Genmethrax，Inc.的首席商务官；Thomas Jefferson Medical University的技术许可经理；Ciba Geigy（诺华）的技术许可经理。Dey先生在印度的Visva-Bharati大学获得了生物化学学士学位和理学硕士学位，并在匈牙利的生物研究中心获得了脂膜生物化学博士学位。他还获得了剑桥大学的工商管理硕士学位（富布赖特奖学金）。
Neil Dey,co-founded Bluejay Diagnostics in 2015. In 2008, Mr. Dey co-founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and EU. During his tenure with LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva-Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's in Business Administration (Fulbright Scholarship) from the University of Cambridge.- Neil Dey于2015年共同创立了Bluejay Diagnostics。2008年，Dey先生联合创立了Lana Management and Business Research International，LLC“；LMBRI”；，并从2008年到2015年担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国，日本和欧盟医疗领域的产品发布和营销。任职LMBRI公司期间，他曾担任Toray Industries公司、Hitachi Chemicals公司（现为Showa Denko Materials Co.Ltd.）、Fujifilm公司（富士化学公司）、Merck&Co公司、SRI International公司等公司的顾问约8年。从2005年到2007年，Dey先生担任Definines，AG的业务开发和市场副总裁。从2001年到2005年，他曾担任Impath公司的美国西部业务开发主管，在那里他曾负责三个业务单元，以及Herceptin公司的乳腺癌治疗的HER2NEU Diagnostics的推出。较早的职位包括Genmethrax，Inc.的首席商务官；Thomas Jefferson Medical University的技术许可经理；Ciba Geigy（诺华）的技术许可经理。Dey先生在印度的Visva-Bharati大学获得了生物化学学士学位和理学硕士学位，并在匈牙利的生物研究中心获得了脂膜生物化学博士学位。他还获得了剑桥大学的工商管理硕士学位（富布赖特奖学金）。
- Neil Dey,co-founded Bluejay Diagnostics in 2015. In 2008, Mr. Dey co-founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and EU. During his tenure with LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva-Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's in Business Administration (Fulbright Scholarship) from the University of Cambridge.
- Jason Cook
Jason Cook于2021年加入我们。从2014年到2021年，Cook博士担任NanoHybrids，Inc.的首席执行官，该公司是一家纳米技术公司，专门从事热疗纳米颗粒平台技术的开发和制造。他还曾担任董事，并于2020年至2021年担任董事会主席，并于2014年至2017年担任高级科学家，开发了公司的许多核心技术。Cook博士在德克萨斯大学奥斯汀分校获得了生物医学工程博士学位，专注于医疗诊断系统的设计和开发。他的博士后工作专注于改进分子靶向纳米颗粒的生物共轭策略。库克博士还担任美国国家健康研究所和同行评审科学期刊的多个小组的临时审稿人。
Jason Cook,joined Bluejay Diagnostics, Inc. in 2021. From 2014 to 2021, Dr. Cook served as the Chief Executive Officer of NanoHybrids, Inc., a nanotechnology company specializing in the development and manufacture of theranostic nanoparticle platform technologies. He was also a Director and served as Chairman of its Board from 2020 to 2021, and from 2014 to 2017, he served as Senior Scientist developing many of the core technologies of the company. Dr. Cook earned a Ph.D. in Biomedical Engineering from the University of Texas at Austin, focusing on medical diagnostic system design and development. His postdoctoral work focused on the improvement of bioconjugation strategies of nanoparticles for molecular targeting. Dr. Cook also serves as an ad-hoc reviewer for numerous panels at the National Institute of Health and peer reviewed scientific journals.- Jason Cook于2021年加入我们。从2014年到2021年，Cook博士担任NanoHybrids，Inc.的首席执行官，该公司是一家纳米技术公司，专门从事热疗纳米颗粒平台技术的开发和制造。他还曾担任董事，并于2020年至2021年担任董事会主席，并于2014年至2017年担任高级科学家，开发了公司的许多核心技术。Cook博士在德克萨斯大学奥斯汀分校获得了生物医学工程博士学位，专注于医疗诊断系统的设计和开发。他的博士后工作专注于改进分子靶向纳米颗粒的生物共轭策略。库克博士还担任美国国家健康研究所和同行评审科学期刊的多个小组的临时审稿人。
- Jason Cook,joined Bluejay Diagnostics, Inc. in 2021. From 2014 to 2021, Dr. Cook served as the Chief Executive Officer of NanoHybrids, Inc., a nanotechnology company specializing in the development and manufacture of theranostic nanoparticle platform technologies. He was also a Director and served as Chairman of its Board from 2020 to 2021, and from 2014 to 2017, he served as Senior Scientist developing many of the core technologies of the company. Dr. Cook earned a Ph.D. in Biomedical Engineering from the University of Texas at Austin, focusing on medical diagnostic system design and development. His postdoctoral work focused on the improvement of bioconjugation strategies of nanoparticles for molecular targeting. Dr. Cook also serves as an ad-hoc reviewer for numerous panels at the National Institute of Health and peer reviewed scientific journals.
- Kenneth Fisher
Kenneth Fisher,2022年3月加入Bluejay Diagnostics公司。费希尔先生是一位经验丰富的金融专业人士和注册会计师。2010年7月至2021年11月，他担任莫里迪恩洲际合众银行公司及其子公司东波士顿储蓄银行（2021年11月与Rockland Trust合并）的执行副总裁、首席财务官和财务主管。在此之前，他曾在Beverly National Bank担任副总裁兼财务主管，并在Parent，McLaughlin & Nangle，CPAs（现为Marcum LLP）担任高级审计师。他在马萨诸塞大学阿默斯特分校伊森伯格管理学院获得工商管理学士学位，并毕业于新英格兰金融研究学院。
Kenneth Fisher,joined Bluejay Diagnostics, Inc. in March 2022. Mr. Fisher is an accomplished financial professional and Certified Public Accountant. From July 2010 to November 2021, he was Executive Vice President, Chief Financial Officer and Treasurer of Meridian Bancorp, Inc. and its subsidiary, East Boston Savings Bank (merged with Rockland Trust in November 2021). Prior to that, he served as Vice President and Treasurer at Beverly National Bank and as a senior auditor at Parent, McLaughlin & Nangle, CPAs (now Marcum LLP). He received his Bachelor's Degree in Business Administration from the Isenberg School of Management at the University of Massachusetts at Amherst and is a graduate of the New England School for Financial Studies.- Kenneth Fisher,2022年3月加入Bluejay Diagnostics公司。费希尔先生是一位经验丰富的金融专业人士和注册会计师。2010年7月至2021年11月，他担任莫里迪恩洲际合众银行公司及其子公司东波士顿储蓄银行（2021年11月与Rockland Trust合并）的执行副总裁、首席财务官和财务主管。在此之前，他曾在Beverly National Bank担任副总裁兼财务主管，并在Parent，McLaughlin & Nangle，CPAs（现为Marcum LLP）担任高级审计师。他在马萨诸塞大学阿默斯特分校伊森伯格管理学院获得工商管理学士学位，并毕业于新英格兰金融研究学院。
- Kenneth Fisher,joined Bluejay Diagnostics, Inc. in March 2022. Mr. Fisher is an accomplished financial professional and Certified Public Accountant. From July 2010 to November 2021, he was Executive Vice President, Chief Financial Officer and Treasurer of Meridian Bancorp, Inc. and its subsidiary, East Boston Savings Bank (merged with Rockland Trust in November 2021). Prior to that, he served as Vice President and Treasurer at Beverly National Bank and as a senior auditor at Parent, McLaughlin & Nangle, CPAs (now Marcum LLP). He received his Bachelor's Degree in Business Administration from the Isenberg School of Management at the University of Massachusetts at Amherst and is a graduate of the New England School for Financial Studies.